Literature DB >> 29513652

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Aparna Gorthi1,2, July Carolina Romero1,2, Eva Loranc2, Lin Cao2, Liesl A Lawrence1,2, Elicia Goodale2, Amanda Balboni Iniguez3,4, Xavier Bernard1,2, V Pragathi Masamsetti2, Sydney Roston5, Elizabeth R Lawlor6, Jeffrey A Toretsky5, Kimberly Stegmaier3,4, Stephen L Lessnick7, Yidong Chen2,8,9, Alexander J R Bishop1,2,8.   

Abstract

Ewing sarcoma is an aggressive paediatric cancer of the bone and soft tissue. It results from a chromosomal translocation, predominantly t(11;22)(q24:q12), that fuses the N-terminal transactivation domain of the constitutively expressed EWSR1 protein with the C-terminal DNA binding domain of the rarely expressed FLI1 protein. Ewing sarcoma is highly sensitive to genotoxic agents such as etoposide, but the underlying molecular basis of this sensitivity is unclear. Here we show that Ewing sarcoma cells display alterations in regulation of damage-induced transcription, accumulation of R-loops and increased replication stress. In addition, homologous recombination is impaired in Ewing sarcoma owing to an enriched interaction between BRCA1 and the elongating transcription machinery. Finally, we uncover a role for EWSR1 in the transcriptional response to damage, suppressing R-loops and promoting homologous recombination. Our findings improve the current understanding of EWSR1 function, elucidate the mechanistic basis of the sensitivity of Ewing sarcoma to chemotherapy (including PARP1 inhibitors) and highlight a class of BRCA-deficient-like tumours.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29513652      PMCID: PMC6318124          DOI: 10.1038/nature25748

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1.

Authors:  Yutaka Suzuki; J Bradley Holmes; Susana M Cerritelli; Kiran Sakhuja; Michal Minczuk; Ian J Holt; Robert J Crouch
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

2.  Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12).

Authors:  C Turc-Carel; I Philip; M P Berger; T Philip; G M Lenoir
Journal:  Cancer Genet Cytogenet       Date:  1984-05

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.

Authors:  L Yang; H A Chansky; D D Hickstein
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2.

Authors:  Jacob C Schwartz; Christopher C Ebmeier; Elaine R Podell; Joseph Heimiller; Dylan J Taatjes; Thomas R Cech
Journal:  Genes Dev       Date:  2012-12-15       Impact factor: 11.361

Review 6.  Transcription as a source of genome instability.

Authors:  Nayun Kim; Sue Jinks-Robertson
Journal:  Nat Rev Genet       Date:  2012-02-14       Impact factor: 53.242

Review 7.  Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.

Authors:  N Riggi; L Cironi; M-L Suvà; I Stamenkovic
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

8.  Prevalent, Dynamic, and Conserved R-Loop Structures Associate with Specific Epigenomic Signatures in Mammals.

Authors:  Lionel A Sanz; Stella R Hartono; Yoong Wearn Lim; Sandra Steyaert; Aparna Rajpurkar; Paul A Ginno; Xiaoqin Xu; Frédéric Chédin
Journal:  Mol Cell       Date:  2016-06-30       Impact factor: 17.970

9.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

Authors:  J Chad Brenner; Felix Y Feng; Sumin Han; Sonam Patel; Siddharth V Goyal; Laura M Bou-Maroun; Meilan Liu; Robert Lonigro; John R Prensner; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2012-01-27       Impact factor: 12.701

10.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

View more
  74 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

2.  Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.

Authors:  Steffi Herold; Jacqueline Kalb; Gabriele Büchel; Carsten P Ade; Apoorva Baluapuri; Jiajia Xu; Jan Koster; Daniel Solvie; Anne Carstensen; Christina Klotz; Sabrina Rodewald; Christina Schülein-Völk; Matthias Dobbelstein; Elmar Wolf; Jan Molenaar; Rogier Versteeg; Susanne Walz; Martin Eilers
Journal:  Nature       Date:  2019-03-20       Impact factor: 49.962

3.  Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Authors:  Caitlin D Lowery; Michele Dowless; Matthew Renschler; Wayne Blosser; Alle B VanWye; Jennifer R Stephens; Philip W Iversen; Aimee Bence Lin; Richard P Beckmann; Kateryna Krytska; Kristina A Cole; John M Maris; Douglas S Hawkins; Brian P Rubin; Raushan T Kurmasheva; Peter J Houghton; Richard Gorlick; E Anders Kolb; Min H Kang; C Patrick Reynolds; Stephen W Erickson; Beverly A Teicher; Malcolm A Smith; Louis F Stancato
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

Review 4.  R-Loops as Cellular Regulators and Genomic Threats.

Authors:  Madzia P Crossley; Michael Bocek; Karlene A Cimprich
Journal:  Mol Cell       Date:  2019-02-07       Impact factor: 17.970

5.  Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription.

Authors:  Linyu Zuo; Guanwei Zhang; Matthew Massett; Jun Cheng; Zicong Guo; Liang Wang; Yifei Gao; Ru Li; Xu Huang; Pilong Li; Zhi Qi
Journal:  Nat Commun       Date:  2021-03-05       Impact factor: 14.919

6.  Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication.

Authors:  Ina Klusmann; Kai Wohlberedt; Anna Magerhans; Federico Teloni; Jan O Korbel; Matthias Altmeyer; Matthias Dobbelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-09       Impact factor: 11.205

7.  Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.

Authors:  Stacia L Koppenhafer; Kelli L Goss; William W Terry; David J Gordon
Journal:  Mol Cancer Res       Date:  2019-10-24       Impact factor: 5.852

8.  Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Authors:  Yang Liu; Joseph M Eckenrode; Yinan Zhang; Jianjun Zhang; Reiya C Hayden; Annet Kyomuhangi; Larissa V Ponomareva; Zheng Cui; Jürgen Rohr; Oleg V Tsodikov; Steven G Van Lanen; Khaled A Shaaban; Markos Leggas; Jon S Thorson
Journal:  J Med Chem       Date:  2020-11-16       Impact factor: 7.446

9.  crisprSQL: a novel database platform for CRISPR/Cas off-target cleavage assays.

Authors:  Florian Störtz; Peter Minary
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

10.  qDRIP: a method to quantitatively assess RNA-DNA hybrid formation genome-wide.

Authors:  Magdalena P Crossley; Michael J Bocek; Stephan Hamperl; Tomek Swigut; Karlene A Cimprich
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.